Chemomab Therapeutics Ltd. Quarterly Retained Earnings (Accumulated Deficit) in USD from Q4 2018 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
Chemomab Therapeutics Ltd. quarterly Retained Earnings (Accumulated Deficit) history and growth rate from Q4 2018 to Q2 2024.
  • Chemomab Therapeutics Ltd. Retained Earnings (Accumulated Deficit) for the quarter ending June 30, 2024 was -$96.2M, a 19.4% decline year-over-year.
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 -$96.2M -$15.6M -19.4% Jun 30, 2024 6-K 2024-08-21
Q4 2023 -$88.7M -$24.9M -39% Dec 31, 2023 6-K 2024-08-21
Q2 2023 -$80.5M -$33.1M -69.7% Jun 30, 2023 6-K 2023-08-14
Q1 2023 -$72.6M -$31.3M -75.8% Mar 31, 2023 10-Q 2023-05-11
Q4 2022 -$63.8M -$27.6M -76.4% Dec 31, 2022 20-F 2024-03-28
Q3 2022 -$55.5M -$24.4M -78.4% Sep 30, 2022 10-Q 2022-11-10
Q2 2022 -$47.5M -$19.3M -68.5% Jun 30, 2022 10-Q 2022-08-12
Q1 2022 -$41.3M -$15.9M -62.5% Mar 31, 2022 10-Q 2022-05-12
Q4 2021 -$36.2M -$12.5M -52.7% Dec 31, 2021 10-K 2023-03-20
Q3 2021 -$31.1M +$83.8M +72.9% Sep 30, 2021 10-Q 2021-11-12
Q2 2021 -$28.2M +$84.3M +74.9% Jun 30, 2021 10-Q 2021-08-13
Q1 2021 -$25.4M +$83.6M +76.7% Mar 31, 2021 10-Q 2021-05-13
Q4 2020 -$23.7M +$81.7M +77.5% Dec 31, 2020 10-K 2022-03-30
Q3 2020 -$115M Sep 30, 2020 10-Q 2020-11-16
Q2 2020 -$112M Jun 30, 2020 10-Q 2020-08-14
Q1 2020 -$109M Mar 31, 2020 10-Q 2020-05-07
Q4 2019 -$105M -$27.1M -34.6% Dec 31, 2019 10-K 2021-03-09
Q4 2018 -$78.3M Dec 31, 2018 10-K 2020-03-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.